A Phase 2 interventional study of Inebilizumab and Blinatumomab in Systemic Lupus Erythematosus and Active Refractory Rheumatoid Arthritis, sponsored by Amgen. Recruiting at 58 sites in 10 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-05.
Sponsored by Amgen · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies in Lupus Erythematosus, Systemic by Amgen — 1 open to participants now, 1 under way, none of them phase 3. Lupus Erythematosus, Systemic · Amgen.
Among the 20 studies in Lupus Erythematosus, Systemic by Amgen, this one is the 2nd largest by planned enrollment, is the only one that started in 2025, is one of 5 in phase 2, and was the 20th registered.
1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.
Browse Lupus Erythematosus, Systemic studies →1 of the 20 studies in Lupus Erythematosus, Systemic by Amgen is open now, in 10 countries.
By country, each count listing its studies:
Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 1 started in 2025.
This study's planned enrollment of 220 is above the median of 52 across 878 interventional studies indexed under Lupus Erythematosus, Systemic.
Median enrollment 56 across the 20 interventional studies. Of the 19 that completed or were terminated, 7 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 20 studies in Lupus Erythematosus, Systemic by Amgen, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The main objective is to assess the safety and tolerability of inebilizumab in adult participants with active and refractory systemic lupus erythematosus (SLE) with nephritis (Subprotocol A) and to assess the safety and tolerability of subcutaneous (SC) blinatumomab in adult participants with active and refractory SLE with and without nephritis (Subprotocol B Part A) and in adult participants with active refractory rheumatoid arthritis (RA) (Subprotocol C Part A). The trial will also assess the efficacy of SC blinatumomab in adult participants with active and refractory SLE with and without nephritis (Subprotocol B Part B and Subprotocol C Part B).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
*Subprotocol A and B are no longer recruiting participants*
Inclusion Criteria:
Subprotocol A and B: Participant must be positive for at least one of the following autoantibodies at screening (performed by central laboratory) or through documented history:
Subprotocol A and B: If receiving any of the following medications, participants must be on these doses prior to Day 1:
Active disease despite having received treatment with:
Inadequate response or intolerance to csDMARDs, bDMARDs, and tsDMARDs should be defined as:
Exclusion Criteria:
Subprotocol A, B and C: Receipt of the following medications or treatments at any time prior to Day 1:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive 3 doses of inebilizumab administered via an intravenous (IV) infusion.
Drug: Inebilizumab
Participants will receive 4 doses of inebilizumab administered via an IV infusion.
Drug: Inebilizumab
Participants will receive blinatumomab low-dose administered via SC injection.
Drug: Blinatumomab
Participants will receive blinatumomab medium-dose administered via SC injection.
Drug: Blinatumomab
Participants will receive blinatumomab high-dose administered via SC injection.
Drug: Blinatumomab
Participants will receive blinatumomab at a dose which will be determined during Subprotocol B Part A.
Drug: Blinatumomab
Participants will receive blinatumomab low-dose administered via SC injection during Subprotocol C Part A.
Drug: Blinatumomab
Participants will receive blinatumomab medium-dose administered via SC injection during Subprotocol C Part A.
Drug: Blinatumomab
Participants will receive blinatumomab high-dose administered via SC injection during Subprotocol C Part A.
Drug: Blinatumomab
Participants will receive blinatumomab at a dose which will be determined during Subprotocol C Part A.
Drug: Blinatumomab
IV Infusion
Also known as: Uplizna®
SC Injection
Subprotocol A, B Part A, and C Part A: Number of Participants Who Experience a Treatment-emergent Adverse Event (TEAE)
Time frame: Day 1 to Week 52
Subprotocol A, B Part A, and C Part A: Number of Participants Who Experience a Serious TEAE
Time frame: Day 1 to Week 52
Subprotocol B Part B Subgroup 1: Number of Participants With Complete Renal Response (CRR)
Time frame: Week 52
Subprotocol B Part B Subgroup 2: Number of Participants With Remission in SLE as Defined by Definition of Remission in SLE (DORIS)
Time frame: Week 26
Subprotocol C Part B: Percentage of Participants Achieving Disease Activity Score-28 Joint C-Reactive Protein (DAS28-CRP) Remission
Time frame: Week 12
Subprotocol A, B Part A Subgroup 1 and Part B Subgroup 1: Number of Participants With CRR
Time frame: Subprotocol A and B Part A: Week 12, Week 26, Week 38, and Week 52; Subprotocol B Part B: Week 12, Week 26, and Week 38
Subprotocol A, B Part A Subgroup 1 and Part B Subgroup 1: Number of Participants With Partial Renal Response (PRR)
Time frame: Week 12, Week 26, Week 38, and Week 52
Subprotocol A and B: Number of Participants With Remission in SLE as Defined by DORIS
Time frame: Subprotocol A, B Part A, and B Part B Subgroup 1: Week 12, Week 26, Week 38, and Week 52; Subprotocol B Part B Subgroup 2: Week 12, Week 38, and Week 52
Subprotocol A and B: Number of Participants With a Lupus Low Disease Activity State (LLDAS)
Time frame: Week 12, Week 26, Week 38, and Week 52
Subprotocol A and B: Change From Baseline in SLE Activity Index-2000 (SLEDAI-2K) Score
Time frame: Week 12, Week 26, Week 38, and Week 52
Subprotocol A, B Part A Subgroup 1 and Part B Subgroup 1: Change From Baseline in 24-hour UPCR
Time frame: Week 12, Week 26, Week 38, and Week 52
Subprotocol A: Maximum Concentration (Cmax) of Inebilizumab
Time frame: Day 1 to Week 52
Subprotocol A: Time to Cmax (tmax) of Inebilizumab
Time frame: Day 1 to Week 52
Subprotocol A: Area Under the Concentration-time Curve (AUC) of Inebilizumab
Time frame: Day 1 to Week 52
Subprotocol B and C: Cmax of Blinatumomab
Time frame: up to Week 12
Subprotocol B and C: tmax of Blinatumomab
Time frame: up to Week 12
Subprotocol B and C: AUC of Blinatumomab
Time frame: up to Week 12
Subprotocol A: Number of Participants With Anti-inebilizumab Antibody Formation
Time frame: Day 1 to Week 52
Subprotocol B and C: Number of Participants With Anti-blinatumomab Antibody Formation
Time frame: Day 1 to Week 52
Subprotocol C Part A: Percentage of Participants Achieving DAS28-CRP < 2.6
Time frame: Week 12 and Week 26
Subprotocol C Part A: Percentage of Participants Achieving Clinical Disease Activity Index (CDAI) ≤ 2.8
Time frame: Week 12 and Week 26
Subprotocol C Part A: Percentage of Participants Achieving Simplified Disease Activity Index (SDAI) ≤ 3.3
Time frame: Week 12 and Week 26
Subprotocol C: Percentage of Participants Achieving American College of Rheumatology (ACR)20 response
Time frame: Week 12 and Week 26
Subprotocol C: Percentage of Participants Achieving ACR50 Response
Time frame: Week 12 and Week 26
Subprotocol C: Percentage of Participants Achieving ACR70 Response
Time frame: Week 12 and Week 26
Subprotocol B Part B and C Part B: Number of Participants Who Experience a TEAE
Time frame: Day 1 to Week 52
Subprotocol B Part B and C Part B: Number of Participants Who Experience a Serious TEAE
Time frame: Day 1 to Week 52
Subprotocol B Part A Subgroup 1 and Part B Subgroup 1: Number of Participants With Primary Efficacy Renal Response (PERR)
Time frame: Week 12, Week 26, Week 38, and Week 52
Subprotocol B Part B Subgroup 2: Number of Participants Who are Responders as Defined by SLE Responder Index 4 (SRI-4)
Time frame: Week 12, Week 26, Week 38, and Week 52
Subprotocol B Part B Subgroup 2: Number of Participants Who are Responders as Defined by SRI-6
Time frame: Week 12, Week 26, Week 38, and Week 52
Subprotocol B Part B Subgroup 2: Number of Participants Who are Responders as Defined by SRI-8
Time frame: Week 12, Week 26, Week 38, and Week 52
Subprotocol B Part B Subgroup 2: Number of Participants Who are Responders as Defined by BILAG-based Combined Lupus Assessment (BICLA)
Time frame: Week 12, Week 26, Week 38, and Week 52
Subprotocol C Part B: Percentage of Participants Achieving DAS28-CRP Remission at Week 26
Time frame: Week 26
Subprotocol C Part B: Percentage of Participants Achieving CDAI Remission at Weeks 12 and 26
Time frame: Week 12 and Week 26
Subprotocol C Part B: Percentage of Participants Achieving SDAI Remission at Weeks 12 and 26
Time frame: Week 12 and Week 26
Subprotocol C Part B: Percentage of Participants Who Achieve DAS28-CRP Remission at Week 12 and Sustain Remission at Weeks 26, 38, and 52
Time frame: Week 12, Week 26, Week 38, and Week 52
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Data sharing requests relating to this trial will be considered beginning 18 months after the trial has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this trial.
Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen trial/trials in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a Data Sharing Independent Review Panel. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the link below.
Data sharing details ↗ · www.amgen.com
Started Jul 2025 (actual). Primary completion is estimated for Aug 2028, 36 months after the start.
Of 67 industry-sponsored phase 2 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 48. This study's planned 36 months is above that.
Counting every sponsor, half of 95 studies reached it within 36 months; a quarter within 27 and three quarters within 56.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Inebilizumab · Blinatumomab
Lupus Erythematosus, Systemic →